{"classes":[{"categories":[{"measurements":[{"comment":"The Median was not reached, and the limits could not be estimated due to the lack of progressive disease by the time of last disease assessment.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The Median was not reached, and the limits could not be estimated due to the lack of progressive disease by the time of last disease assessment.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Response duration was defined as the time from first documented evidence of at least a partial response (sCR+CR+VGPR+PR\\]), until confirmed disease progression or death. DOR was calculated from product-limit (Kaplan-Meier) method for censored data. This is an event-driven (events of disease progression and death) outcome measure. At the time of data cut-off, there were an insufficient number of events from the censored data to be able to estimate certain parameters (e.g. medians). Full Range is the minimum and maximum of the observed duration of response. The data cutoff date was July 9, 2018.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.","id":"OG000","title":"Pembrolizumab + Lenalidomide + Dexamethasone"},{"description":"Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.","id":"OG001","title":"Lenolidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all randomized participants who demonstrated at least a partial response. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 30 months","title":"Duration of Response (DOR) Evaluated According to IMWG Response Criteria by CAC Blinded Central Review","type":"SECONDARY","unitOfMeasure":"Months"}